Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 1,880,000 shares, a decline of 18.6% from the January 15th total of 2,310,000 shares. Currently, 8.0% of the company’s stock are sold short. Based on an average trading volume of 352,500 shares, the short-interest ratio is presently 5.3 days.

Lexeo Therapeutics Stock Performance

Shares of LXEO opened at $4.50 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The firm has a 50-day moving average of $6.04 and a 200-day moving average of $8.33. The company has a market cap of $148.80 million, a PE ratio of -1.42 and a beta of 2.99. Lexeo Therapeutics has a one year low of $3.84 and a one year high of $19.50.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of institutional investors have recently bought and sold shares of LXEO. Frazier Life Sciences Management L.P. acquired a new position in shares of Lexeo Therapeutics during the 3rd quarter worth approximately $11,307,000. Janus Henderson Group PLC boosted its position in Lexeo Therapeutics by 18.9% during the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after purchasing an additional 599,203 shares during the period. Altium Capital Management LLC acquired a new position in shares of Lexeo Therapeutics in the fourth quarter valued at $2,665,000. Point72 Asset Management L.P. bought a new position in shares of Lexeo Therapeutics in the third quarter valued at about $3,348,000. Finally, Verition Fund Management LLC raised its position in shares of Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after purchasing an additional 355,928 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on LXEO shares. Chardan Capital lifted their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Leerink Partners decreased their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Finally, HC Wainwright upped their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.